Clinical Trial Update: Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women [Phase 1, Phase 2]

View source ↗

Summary

Results from a completed Phase 1/2 trial of DARE-HRT1 over 12 weeks in healthy postmenopausal women have been posted. The study targeted vulvovaginal atrophy an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vasomotor Symptoms
• Vulvovaginal Atrophy

Drugs mentioned

• DARE-HRT1

Snippet

Sponsor: Daré Bioscience, Inc. | Conditions: Vulvovaginal Atrophy, Vasomotor Symptoms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-10-31